Accessible Search Form           Advanced Search

10. Research and Development Contracts


NHLBI Research and Development Contract Obligations:* Fiscal Years 1999–2009

NHLBI Research and Development Contract Obligations*:  Fiscal Years 1998-2008

Text-only With Data Points

* For detailed data on contract-supported clinical trials, see Chapter 11.

NHLBI Total Research and Development Contract Obligations: Fiscal Years 1999–2009

Dollars (Thousands)

 

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

FY 2008

FY 2009

Heart

$156,370

$156,415

$184,491

$214,971

$258,647

$245,881

$219,796

$213,320

$260,205

$296,445

$321,223

Lung

25,432

23,341

10,993

16,578

11,745

14,131

20,946

25,902

15,191

20,249

17,710

Blood

15,436

21,538

24,572

26,751

20,082

25,460

27,831

23,629

20,446

22,093

22,164

Total

$197,238A

$201,294B

$220,056C

$258,300D

$290,474E

$285,472F

$268,573G

$262,851H

$295,842I

$338,787J

$361,097K


A Includes Program Evaluation and IMPAC II Assessments of $14,904,000.
B Includes Program Evaluation and IMPAC II Assessments of $17,944,000.
C Includes Program Evaluation and IMPAC II Assessments of $24,579,000.
D Includes Program Evaluation and IMPAC II Assessments of $35,827,000.
E Includes Program Evaluation and IMPAC II Assessments of $54,550,000.
F Includes Program Evaluation and IMPAC II Assessments of $57,545,722.
G Includes Program Evaluation and IMPAC II Assessments of $64,399,000.
H Includes Program Evaluation and IMPAC II Assessments of $67,795,000.
I Includes Program Evaluation and IMPAC II Assessments of $68,405,000.
J EIncludes Program Evaluation and IMPAC II Assessments of $77,487,000.
K Includes Program Evaluation and IMPAC II Assessments of $79,693,000.
Note: From 1999 to 2006 the WHI was reported separately. In this table, it has been incorporated in the "Heart" line.

Back to Top

Major NHLBI Research and Development Contracts by Program

 

Total Obligations Prior to FY 2009

Total FY 2009 Obligations

Total Obligations to Date

Heart and Vascular Diseases

     
Atherosclerosis Risk in Communities (ARIC)

$142,401,024

$7,311,416

$149,712,440

Candidate Gene Association Research

18,220,930

4,199,645

22,420,575

Cardiovascular Health Study (CHS)

78,051,026

702,999

78,754,025

Coronary Artery Risk Development in Young Adults (CARDIA)

88,529,300

9,834,016

98,363,316

DNA Resequencing and Genotyping

25,352,366

1,277,670

26,630,036

Framingham Heart Study

99,133,876

14,499,000

113,632,876

Genetically Triggered Thoracic Aortic Aneurysms and Other Cardiovascular Conditions (GENTAC): National Registry

4,808,249

1,937,221

6,745,470

Global Health Centers of Excellence

13,399,780

13,399,780

Hispanic Community Health Study (HCHS)

39,784,884

11,454,663

51,239,547

Jackson Heart Study (JHS)

32,796,573

5,610,000

38,406,573

Multi-Ethnic Study of Atherosclerosis (MESA)

76,518,417

24,757,152

101,275,569

NHLBI Gene Therapy Resource Program (GTRP)

11,800,000

7,327,735

19,127,735

Pediatric Circulatory Support

22,195,025

1,101,398

23,296,423

Proteomics Initiative

157,606,085

157,606,085

Randomized Trial of Genotype-Guided Dosing of Warfarin Therapy

2,637,062

3,530,000

6,167,062

Registry for Mechanical Circulatory Support

5,061,898

1,277,005

6,338,903

Lung Diseases

 

 

 

Lung Tissue Research Consortium

23,874,972

2,629,236

26,504,208

Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)

594,954

594,954

Tuberculosis Curriculum Coordinating Center

6,000,000

787,728

6,787,728

Blood Diseases and Resources

 

 

 

Maintenance of NHLBI Biological Specimen Repository

13,367,735

4,296,738

17,664,473

NHLBI–CDC Registry and Surveillance System in Hemoglobinopathies (RuSH)

1,506,239

1,506,239

Retrovirus Epidemiology Donor Study II (REDS-II)

37,213,866

6,377,477

43,591,343

Somatic Cell Therapy Processing Facilities

21,750,926

1,999,855

23,750,781

Back to Top

Heart and Vascular Diseases Program

Atherosclerosis Risk in Communities (ARIC), Initiated in Fiscal Year 1985

The ARIC is a large, longitudinal study comprising a community surveillance component and a prospective cohort component to investigate the etiology of atherosclerosis and its clinical sequelae and variation in cardiovascular risk factors by race, gender, and location. The community surveillance component monitors trends in hospitalized myocardial infarction, fatal CHD, and heart failure (2005–2009) by race and gender in four U.S. communities. The cohort component investigates the etiology of CHD in 15,792 participants, aged 46–64 at baseline, who were selected from the same communities. The participants received an extensive examination upon entry into the study (1987–1989) that included gathering medical, social, and demographic data. Subsequent examinations occurred in 1990–1992, 1993–1995, and 1996–1998, followed by contact annually by telephone to assess the health status of the cohort. Beginning in 2011, the study will reexamine the cohort participants with a focus on heart failure—a major epidemic in the rapidly aging population in the United States. Three of the cohort components represent the racial mix of their community, and the fourth is exclusively black.

Obligations

Funding History:
Fiscal Year 2009—$7,311,416
Fiscal Years 1985–2008—$142,401,024
Total Funding to Date—$149,712,440

Current Active Organizations and Contract Numbers

  1. University of North Carolina at
    Chapel Hill
    Chapel Hill, North Carolina —HC-55015
  2. Baylor College of Medicine
    Houston, Texas —HC-55016
  3. University of North Carolina at
    Chapel Hill
    Chapel Hill, North Carolina —HC-55018
  4. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HC-55019
  5. Johns Hopkins University
    Baltimore, Maryland —HC-55020
  6. Mississippi Medical Center
    Jackson, Mississippi —HC-55021

Candidate Gene Association Resources, Initiated in Fiscal Year 2006

This program establishes a genotyping and bioinformatics center to perform high-throughput genotyping for candidate gene association studies in up to 50,000 participants, and a genome-wide association study in about 500 disease cases and 1,000 controls. The data will be combined with available phenotype data to form a genotype–phenotype resource for public use. DNA for the 50,000-person sample will be collected from multiple NHLBI cohort studies that have stored samples and available data on a wide array of heart, lung, blood, and sleep phenotypes.

Obligations

Funding History:
Fiscal Year 2009—$4,199,645
Fiscal Years 2006–2008—$18,220,930
Total Funding to Date—$22,420,575

Current Active Organization and Contract Number

  1. Massachusetts Institute of Technology
    Cambridge, Massachusetts —HC-65226

Cardiovascular Health Study (CHS), Initiated in Fiscal Year 1988

The CHS is a population-based, longitudinal study of risk factors for development and progression of CHS and stroke in elderly adults, 17 percent of whom are from minority populations. Extensive data and samples have been collected from nearly 6,000 participants since 1989–1990. The current CHS: Transition Phase provides partial support for an infrastructure to enable continued access to study resources and expertise, scientific collaborations, and mentorship of early-career investigators.

Obligations

Funding History:
Fiscal Year 2009—$702,999
Fiscal Years 1988–2008—$78,051,026
Total Funding to Date—$78,754,025

Current Active Organization and Contract Number

  1. University of Washington
    Seattle, Washington —HC-85239

Coronary Artery Risk Development in Young Adults (CARDIA), Initiated in Fiscal Year 1984

CARDIA is a long-term study examining the evolution of CVD risk factors in a cohort of black and white adults, aged 18 to 30 years in 1985–1986. The study examines risk factors for heart and lung diseases by collecting information on body mass index, physical activity and lifestyle, genetics, serologic and metabolic components, inflammatory markers, and other subclinical measures of disease. Fifty percent of the participants are black.

Obligations

Funding History:
Fiscal Year 2009—$9,834,016
Fiscal Years 1984–2008—$88,529,300
Total Funding to Date—$98,363,316

Current Active Organizations and Contract Numbers

  1. University of Alabama at Birmingham
    Birmingham, Alabama —HC-48047
  2. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HC-48048
  3. Northwestern University
    Chicago, Illinois —HC-48049
  4. Kaiser Permanente Division of Research
    Oakland, California —HC-48050
  5. University of Alabama at Birmingham
    Birmingham, Alabama —HC-95095

DNA Resequencing and Genotyping, Initiated in Fiscal Year 2004

The purpose of this program is to obtain rapid, reliable, and cost-efficient DNA sequencing and genotyping of candidate genomic regions potentially important in the disease pathways of heart, lung, and blood diseases and sleep disorders. This information will assist ongoing investigations of genetic components involved in the causes, variable outcome, and progression of the diseases and disorders.

Obligations

Funding History:
Fiscal Year 2009—$1,277,670
Fiscal Years 2004–2008—$25,352,366
Total Funding to Date—$26,630,036

Current Active Organizations and Contract Numbers

  1. Constella
    Rockville, Maryland —HV-48193
  2. Johns Hopkins University
    Baltimore, Maryland —HV-48195
  3. J. Craig Venter Institute, Inc.
    Rockville, Maryland —HV-48196

Framingham Heart Study

The original Framingham Heart Study was designed as a longitudinal investigation of constitutional and environmental factors influencing the development of CVD in individuals free of these conditions at the outset. Of the original 5,209 subjects, about 400 members remain alive. In 1971, the Framingham Offspring Study was initiated to assess familial and genetic factors associated with CHD. More than 5,000 offspring (and their spouses) were included. A third-generation cohort consisting of approximately 4,000 grandchildren has been added to permit examination of numerous hypotheses about the genetic contribution to CVD and CVD risk factors. Additional goals include identifying new risk factors for cardiovascular, lung, and blood diseases and developing new imaging tests that can detect very early stages of coronary atherosclerosis in otherwise healthy adults.

Obligations

Funding History:
Fiscal Year 2009—$14,499,000
Fiscal Years 1983–2008—$99,133,876
Total Funding to Date—$113,632,876

Current Active Organization and Contract Number

  1. Boston University Medical Center
    Boston, Massachusetts —HC-25195

Genetically Triggered Thoracic Aortic Aneurysms and Other Cardiovascular Conditions (GENTAC): National Registry, Initiated in Fiscal Year 2006

The purpose of this program is to establish a national registry to enable investigators to determine the best medical practices to advance the clinical management of genetic thoracic aortic aneurysms and other cardiovascular complications associated with connective tissue diseases such as Marfan, Loeys-Dietz, and Ehlers Danlos (vascular type) Syndromes.

Obligations

Funding History:
Fiscal Year 2009—$1,937,221
Fiscal Years 2006–2008—$4,808,249
Total Funding to Date—$6,745,470

Current Active Organization and Contract Number

  1. Research Triangle Institute
    Research Triangle Park, North Carolina —HV-68199

Global Health Centers of Excellence, Initiated in Fiscal Year 2009

The purpose of this program is to support a worldwide network of research and training centers to prevent and control chronic diseases, such as cardiovascular diseases, lung diseases, and diabetes. The NHLBI joined with Minneapolis-based UnitedHealth Group's Chronic Disease Initiative in establishing the UnitedHealth and NHLBI Collaborating Centers of Excellence network. Each center is led by a research institution in a low- or middle-income, developing country that is paired with at least one partner academic institution in a developed country to enhance research and training opportunities.

Obligations

Funding History
Fiscal Year 2009—$13,399,780
Total Funding to Date—$13,399,780

Current Active Organizations and Contract Numbers

  1. St. John's Research Institute
    Karnataka, India —HV-98215
  2. Public Health Foundation in India
    New Delhi, India —HV-98216
  3. The George Institutes in China
    Beijing, China —HV-98217
  4. Instituto de Nutrición de Centro América
    Guatemala City, Guatemala —HV-98218
  5. Institute for Clinical Effectiveness
    and Health Policy
    Buenos Aires, Argentina —HV-98219
  6. University of Cape Town
    Cape Town, South Africa —HV-98220
  7. Moi University School of Medicine
    Eldoret, Kenya —HV-98221
  8. International Center for Diarrhoeal
    Disease Branch
    Mohakhali, Bangladesh —HV-98222
  9. University of Peruana
    San Martin, Peru —HV-98223
  10. Westat
    Rockville, Maryland —HV-98224

Hispanic Community Health Study (HCHS), Initiated in Fiscal Year 2006

The purpose of this program is to determine the prevalence of and risk factors for cardiovascular and lung diseases in Hispanic populations and the role of cultural adaptation and disparities in development of these and other chronic diseases. The program is supporting a multicenter, 6.5-year epidemiology study comprising approximately 16,000 participants aged 18–74 years with diverse backgrounds, including Americans of Mexican, Puerto Rican, Cuban American, and Central/South American descent, 4,000 at each of 4 sites.

Obligations

Funding History:
Fiscal Year 2009—$11,454,663
Fiscal Years 2006–2008—$39,784,884
Total Funding to Date—$51,239,547

Current Active Organizations and Contract Numbers

  1. University of North Carolina at
    Chapel Hill
    Chapel Hill, North Carolina —HC-65233
  2. University of Miami
    Miami, Florida —HC-65234
  3. Albert Einstein College of Medicine
    New York, New York —HC-65235
  4. Northwestern University
    Chicago, Illinois —HC-65236
  5. San Diego State University
    San Diego, California —HC-65237

Jackson Heart Study (JHS), Initiated in Fiscal Year 1998

The JHS is a single-site, epidemiologic study of CVD in blacks, similar to established studies in Framingham, Massachusetts, and Honolulu, Hawaii, with primary goals of identifying risk factors for development and progression of CVD; enhancing retention; building research capabilities at minority institutions; developing partnerships between minority and majority institutions; and expanding minority investigator participation in large-scale, epidemiologic studies.

Obligations

Funding History:
Fiscal Year 2009—$5,610,000
Fiscal Years 1998–2008—$32,796,573
Total Funding to Date—$38,406,573

Current Active Organizations and Contract Numbers

  1. Jackson State University
    Jackson, Mississippi —HC-95170
  2. Mississippi Medical Center
    Jackson, Mississippi —HC-95171
  3. Tougaloo College
    Tougaloo, Mississippi —HC-95172

Multi-Ethnic Study of Atherosclerosis (MESA), Initiated in Fiscal Year 1999

The purpose of this study is to investigate the prevalence, correlates, and progression of subclinical CVD, i.e., disease detected noninvasively before it has produced clinical signs and symptoms, in a population that is 38 percent white, 28 percent black, 22 percent Hispanic, and 12 percent Asian. Plans are underway for a fifth examination to begin in 2010 that will include a measurement of cardiac function with MRI. Periodic monitoring of participants to identify recent hospitalizations and other clinical events will continue.

Obligations

Funding History:
Fiscal Year 2009—$24,757,152
Fiscal Years 1999–2008—$76,518,417
Total Funding to Date—$101,275,569

Current Active Organizations and Contract Numbers

  1. University of Washington
    Seattle, Washington —HC-95159
  2. University of California, Los Angeles
    Los Angeles, California —HC-95160
  3. Columbia University
    New York, New York —HC-95161
  4. Johns Hopkins University
    Baltimore, Maryland —HC-95162
  5. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HC-95163
  6. Northwestern University
    Chicago, Illinois —HC-95164
  7. Wake Forest University
    Winston-Salem, North Carolina —HC-95165
  8. University of Vermont
    Colchester, Vermont —HC-95166
  9. New England Medical Center
    Boston, Massachusetts —HC-95167
  10. Johns Hopkins University
    Baltimore, Maryland —HC-95168
  11. Harbor-UCLA Research and
    Education Institute
    Los Angeles, California —HC-95169

NHLBI Gene Therapy Resource Program (GTRP), Initiated in Fiscal Year 2007

The purpose of this program is to promote the translation of basic research into clinical trials. The program will support the production of safe and well-characterized vectors; conduct extensive toxicology and pharmacology studies on animals to determine vector dosing, related toxicity, and vector dissemination; and provide investigators with regulatory assistance to initiate a clinical trial. The GTRP also will support a maximum of two phase I/II gene transfer clinical trials per year that have successfully met all regulatory requirements and are ready to enroll patients within 12 months of application approval.

Obligations

Funding History:
Fiscal Year 2009—$7,327,735
Fiscal Year 2008—$11,800,000
Total Funding to Date—$19,127,735

Current Active Organizations and Contract Numbers

  1. Social and Scientific Systems, Inc.
    Silver Spring, Maryland —HV-78200
  2. Lovelace Biomedical Research &
    Education Institute
    Albuquerque, New Mexico —HV-78201
  3. University of Pennsylvania
    Philadelphia, Pennsylvania —HV-78202
  4. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HV-78203
  5. Indiana University
    Indianapolis, Indiana —HV-78204

Pediatric Circulatory Support, Initiated in Fiscal Year 2004

The purpose of this program is to establish multidisciplinary teams to develop innovative circulatory assist devices or other bioengineered systems for infants and children with congenital and acquired CVD who experience cardiopulmonary failure and circulatory collapse.

Obligations

Funding History:
Fiscal Year 2009—$1,101,398
Fiscal Years 2004–2008—$22,195,025
Total Funding to Date—$23,296,423

Current Active Organizations and Contract Numbers

  1. Cleveland Clinic
    Lerner College of Medicine
    Cleveland, Ohio —HV-48188
  2. Ension, Inc.
    Pittsburgh, Pennsylvania —HV-48189
  3. Jarvik Heart, Inc.
    New York, New York —HV-48190
  4. Pennsylvania State University
    Hershey, Pennsylvania —HV-48191
  5. University of Pittsburgh
    Pittsburgh, Pennsylvania —HV-48192

Proteomics Initiative, Initiated in Fiscal Year 2002

The purpose of this program is to establish highly interactive, multidisciplinary centers to enhance and develop innovative proteomic technologies directed to relevant biologic questions associated with heart, lung, blood, and sleep health and disease. Scientists will focus on the cells' protein machinery directed toward understanding the molecular basis of the causes and progression of heart, lung, and blood diseases and sleep disorders and identifying targets for therapeutic interventions.

Obligations

Funding History:
Fiscal Year 2009—$0
Fiscal Years 2002–2008—$157,606,085
Total Funding to Date—$157,606,085

Current Active Organizations and Contract Numbers

  1. Boston University
    Boston, Massachusetts —HV-28178
  2. Institute for Systems Biology
    Seattle, Washington —HV-28179
  3. Johns Hopkins University
    Baltimore, Maryland —HV-28180
  4. Medical University of South Carolina
    Charleston, South Carolina —HV-28181
  5. Medical College of Wisconsin
    Milwaukee, Wisconsin —HV-28182
  6. Stanford University
    Stanford, California —HV-28183
  7. University of Texas
    Galveston, Texas —HV-28184
  8. University of Texas
    Southwestern Medical Center
    Dallas, Texas —HV-28185
  9. Yale University
    New Haven, Connecticut —HV-28186
  10. Henry M. Jackson Foundation for the
    Advancement of Military Medicine, Inc.
    Rockville, Maryland —HV-28187

Randomized Trial of Genotype-Guided Dosing of Warfarin Therapy, Initiated in Fiscal Year 2008

See Chapter 11. Clinical Trials.

Registry for Mechanical Circulatory Support, Initiated in Fiscal Year 2005

The purpose of this program is to establish a data and clinical coordinating center to manage a registry of patients receiving an FDA-approved mechanical circulatory support device (MCSD) to treat heart failure. The registry will collect and analyze clinical and laboratory data and tissue samples from patients who receive MCSDs as destination therapy for end-stage heart failure at 90 to 100 participating hospitals.

Obligations

Funding History:
Fiscal Year 2009—$1,277,005
Fiscal Years 2005–2008—$5,061,898
Total Funding to Date—$6,338,903

Current Active Organization and Contract Number

  1. University of Alabama
    Birmingham, Alabama —HV-58198

Lung Diseases Program

Lung Tissue Research Consortium, Initiated in Fiscal Year 2004

The purpose of this program is to establish a consortium for collecting lung tissues and preparing and distributing them for research. Scientists seek to improve management of lung diseases by increasing understanding of the pathogenetic mechanisms of lung diseases through molecular histopathological studies on tissues with and without disease. Primary emphases are on COPD and idiopathic pulmonary fibrosis.

Obligations

Funding History:
Fiscal Year 2009—$2,629,236
Fiscal Years 2004–2008—$23,874,972
Total Funding to Date—$26,504,208

Current Active Organizations and Contract Numbers

  1. Mayo Clinic College of Medicine
    Rochester, New York —HR-46158
  2. University of Colorado
    Health Science Center
    Denver, Colorado —HR-46159
  3. Mayo Clinic College of Medicine
    Rochester, New York —HR-46161
  4. University of Michigan
    Ann Arbor, Michigan —HR-46162
  5. University of Pittsburgh
    Pittsburgh, Pennsylvania —HR-46163
  6. Clinical Trials and Survey Corporation
    Baltimore, Maryland —HR-46164

Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials.

Tuberculosis Curriculum Coordinating Center, Initiated in Fiscal Year 2003

The purpose of this program is to establish a consortium of five Tuberculosis Curriculum Centers to strengthen and increase access to the best ongoing educational and training opportunities in TB for medical, nursing, and allied health schools, especially those that provide primary care to communities where TB is endemic and the population is at high risk.

Obligations

Funding History:
Fiscal Year 2009—$787,728
Fiscal Years 2003–2008—$6,000,000
Total Funding to Date—$6,787,728

Current Active Organization and Contract Number

  1. University of California, San Diego
    La Jolla, California —HR-36157

Blood Diseases and Resources Program

Maintenance of NHLBI Biological Specimen Repository, Initiated in Fiscal Year 1998

The purpose of this project is to establish an NHLBI Biological Specimen Repository for blood specimens from Institute-supported research. The Repository monitors storage, labeling, and testing of the specimens, as well as administers safe shipment of precise sample aliquots to approved investigators for future studies.

Obligations

Funding History:
Fiscal Year 2009—$4,296,738
Fiscal Years 1998–2008—$13,367,735
Total Funding to Date—$17,664,473

Current Active Organization and Contract Number

  1. SeraCare Life Sciences, Inc.
    Rockville, Maryland —HB-87144

NHLBI–CDC Registry and Surveillance System in Hemoglobinopathies (RuSH), Initiated in Fiscal Year 2009

The purpose of this program is to develop and implement a national data system and biospecimen repository that will provide data to describe the epidemiologic and clinical characteristics of people who have all genotypes of SCD, thalassemias, and other hemoglobinopathies. The system will be designed to collect, analyze, interpret, and disseminate data on the epidemiology, clinical correlates, health care use, and community resources of patients who have these conditions. It will support research, information dissemination, policy decisions, health care planning, and provider training at the local, state, and national levels.

Obligations

Funding History:
Fiscal Year 2009—$1,506, 239
Total Funding to Date—$1,506, 239

Current Active Organization and Contract Number

  1. Centers for Disease Control and Prevention
    Atlanta, Georgia —HR-9045

Retrovirus Epidemiology Donor Study-II (REDS-II), Initiated in Fiscal Year 2005

The purpose of the program is to conduct epidemiologic, laboratory, and survey research on volunteer blood donors within the United States to ensure the safety and availability of the blood supply. The study seeks to assess the prevalence and incidence of existing as well as newly discovered infectious agents that pose a threat to blood safety; evaluate characteristics and behaviors of voluntary blood donors; determine the causes of adverse transfusion reactions of unknown etiology; assess new and existing blood donor screening methodologies; assess the impact of new blood bank technologies on blood safety and availability; and evaluate the donation process for ways to improve the adequacy of the blood supply.

An international component was added to conduct epidemiologic, laboratory, and survey research on blood donors in China and Brazil, two countries seriously affected by the AIDS epidemic, to ensure the availability and safety of blood for transfusion.

Obligations

Funding History:
Fiscal Year 2009—$6,377,477
Fiscal Years 2005–2008—$37,213,866
Total Funding to Date—$43,591,343

Current Active Organizations and Contract Numbers

  1. Blood Center of Southeastern Wisconsin
    Milwaukee, Wisconsin —HB-47168
  2. American Red Cross Blood Service,
    New England
    Farmington, Connecticut —HB-47169
  3. Emory University
    Atlanta, Georgia —HB-47170
  4. University of Cincinnati
    Cincinnati, Ohio —HB-47171
  5. Institute for Transfusion Medicine
    Pittsburgh, Pennsylvania —HB-47172
  6. University of California, San Francisco
    San Francisco, California —HB-47174
  7. Westat, Inc.
    Rockville, Maryland —HB-47175
  8. Blood System Research, Inc.
    San Francisco, California —HB-57181

Somatic Cell Therapy Processing Facilities, Initiated in Fiscal Year 2003

This program is designed to develop novel somatic cellular therapies in areas ranging from basic science through animal studies to proof-of-principle and eventually human trials for heart, lung, and blood diseases and sleep disorders. The goal is to provide rapid, safe translation of basic research ideas into clinical practice.

Obligations

Funding History:
Fiscal Year 2009—$1,999,855
Fiscal Years 2003–2008—$21,750,926
Total Funding to Date—$23,750,781

Current Active Organizations and Contract Numbers

  1. Baylor College of Medicine
    Houston, Texas —HB-37163
  2. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HB-37164
  3. University of Pittsburgh
    Pittsburgh, Pennsylvania —HB-37165
  4. The EMMES Corporation
    Rockville, Maryland —HB-37166

Back to Top

« Back

Next »

Fact Book Table of Contents

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon